{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T21:46:36Z","timestamp":1765143996900,"version":"3.46.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.braindev.2025.104460","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:45:39Z","timestamp":1759149939000},"page":"104460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy advancements in Duchenne muscular dystrophy: Overlooked challenges"],"prefix":"10.1016","volume":"47","author":[{"given":"Daniel","family":"Matovu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2025.104460_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2025.104424","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"47","author":"Shimizu-Motohashi","year":"2025","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2025.104460_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2025.104460_bb0015","doi-asserted-by":"crossref","first-page":"1569289","DOI":"10.3389\/fgene.2025.1569289","article-title":"Improving the therapeutic efficacy of gene therapy for Duchenne muscular dystrophy (DMD) by evaluating and managing inflammation","volume":"16","author":"Raghavan","year":"2025","journal-title":"Front Genet"},{"key":"10.1016\/j.braindev.2025.104460_bb0020","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.ymthe.2024.07.026","article-title":"Full-length dystrophin gene therapy for Duchenne muscular dystrophy","volume":"32","author":"Duan","year":"2024","journal-title":"Mol Ther"},{"year":"2025","series-title":"Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy? Gene Ther","author":"G\u00f3recki","key":"10.1016\/j.braindev.2025.104460_bb0025"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:58:43Z","timestamp":1764403123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760425001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0387760425001421"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104460","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy advancements in Duchenne muscular dystrophy: Overlooked challenges","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104460"}}